Combinación de Ribociclib y Terapia Endocrina en Pacientes con Cáncer de Mama Temprano, Positivo a Receptores Hormonales y Negativo a HER2

Francisco Javier Esteva, MD, PhD, interim chief, Division of Hematology/Oncology, chief, breast medical oncology, Lenox Hill Hospital; director, Breast Medical Oncology, Northwell Health, discusses key findings from the phase 3 NATALEE trial (NCT03701334) in patients with hormone receptor–positive, HER2-negative early breast cancer.

Esteva: One of the most important studies presented at the [2023] ASCO [Annual] Meeting in Chicago, [Illinois], was the NATALEE study in patients with early-stage breast cancer treated with ribociclib (Kisqali) in combination with endocrine treatments, which are hormonal treatments. The combination of ribociclib with hormonal therapy reduces the risk of recurrence in breast cancer patients by 25.2%, which is 3.3% in absolute numbers. It should be noted that 90.4% of patients did not experience recurrence, which translates to a 25% relative risk reduction at 3 years. This is a very important clinical trial that included 5,101 women with high-risk early-stage breast cancer. The study showed a significant improvement in disease-free survival rate in patients with node-negative and node-positive breast cancer. This is one of the most important studies presented at ASCO this year.

Editor's Note: Dr Esteva's transcript has been translated from Spanish to English.